TY - JOUR
T1 - Effect of two doses of docosahexaenoic acid (DHA) in the diet of preterm infants on infant fatty acid status
T2 - Results from the DINO trial
AU - Smithers, L. G.
AU - Gibson, R. A.
AU - McPhee, A.
AU - Makrides, M.
N1 - Funding Information:
This work was supported with grants from the Channel 7 Children's Research Fund and the University of Adelaide. Salary for MM and RAG is from the Senior Research Fellowship Scheme of the National Health and Medical Research Council of Australia. Clover Corporation, Sydney, Australia, donated the tuna and soy oil capsules used in this trial. Clover Corporation did not have any role in the study design, collection, analysis or interpretation of the data, writing of the document or decision to submit the manuscript for publication. The authors have no financial interest in the production or sales of nutritional supplements. MM and RAG serve on scientific advisory boards of companies that manufacture infant formula.
PY - 2008/9
Y1 - 2008/9
N2 - Formula supplemented with docosahexaenoic acid (DHA) improves retinal function of preterm infants but the optimal dose is unknown. In a randomized controlled trial we examined the effect of increasing the DHA concentration of human milk and formula on circulating fatty acids of preterm infants. Infants born <33 weeks gestation were fed high-DHA milk (1% total fat as DHA) or standard-DHA milk (0.2-0.3% DHA) until reaching their estimated due date (EDD). Milk arachidonic acid (AA) concentration was ∼0.5% for both groups. At EDD, erythrocyte membrane phospholipid DHA was elevated in the high-DHA group compared with standard-DHA (mean±SD, high-DHA 6.8±1.2, standard-DHA 5.2±0.7, p<0.0005) but AA was lower (high-DHA 14.9±1.3, standard-DHA 16.0±1.2, p<0.0005). Feeding preterm infants human milk and formula with 1% DHA raises but does not saturate erythrocyte phospholipids with DHA. Milk exceeding 1% DHA may be required to increase DHA status to levels seen in term infants.
AB - Formula supplemented with docosahexaenoic acid (DHA) improves retinal function of preterm infants but the optimal dose is unknown. In a randomized controlled trial we examined the effect of increasing the DHA concentration of human milk and formula on circulating fatty acids of preterm infants. Infants born <33 weeks gestation were fed high-DHA milk (1% total fat as DHA) or standard-DHA milk (0.2-0.3% DHA) until reaching their estimated due date (EDD). Milk arachidonic acid (AA) concentration was ∼0.5% for both groups. At EDD, erythrocyte membrane phospholipid DHA was elevated in the high-DHA group compared with standard-DHA (mean±SD, high-DHA 6.8±1.2, standard-DHA 5.2±0.7, p<0.0005) but AA was lower (high-DHA 14.9±1.3, standard-DHA 16.0±1.2, p<0.0005). Feeding preterm infants human milk and formula with 1% DHA raises but does not saturate erythrocyte phospholipids with DHA. Milk exceeding 1% DHA may be required to increase DHA status to levels seen in term infants.
UR - http://www.scopus.com/inward/record.url?scp=56449085877&partnerID=8YFLogxK
U2 - 10.1016/j.plefa.2008.09.015
DO - 10.1016/j.plefa.2008.09.015
M3 - Article
C2 - 18951004
AN - SCOPUS:56449085877
SN - 0952-3278
VL - 79
SP - 141
EP - 146
JO - Prostaglandins Leukotrienes and Essential Fatty Acids
JF - Prostaglandins Leukotrienes and Essential Fatty Acids
IS - 3-5
ER -